Harrow Health, Inc. Announces Launch of Mayfield Pharmaceuticals; to Appoint Melissa Bradford-Klug to Lead Mayfield Pharmaceuticals, Inc
July 31, 2019 at 05:00 pm IST
Share
Harrow Health, Inc. announced it has filed a Form 8-K with the Securities and Exchange Commission containing a corporate presentation for its subsidiary, Mayfield Pharmaceuticals, Inc. Mayfield is focused on making a difference in women's lives by developing branded pharmaceutical products that address significant unmet needs within the women's health marketplace.
Harrow expects Mayfield to be led by Melissa Bradford-Klug, an experienced senior life science executive with a proven track record of success. As CEO of Mayfield, Bradford-Klug will be charged with the development of Mayfield's drug candidate pipeline.
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
HARROW, INC. 
